Incyte Corporation (INCY), BioMarin Pharmaceutical Inc. (BMRN): Two Biotech Stocks That Could Be on Novartis AG (ADR) (NVS)’s Buyout Radar

Page 1 of 2

Novartis AG (ADR) (NYSE:NVS)The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is really beginning to heat up, and it’s offering investors an in-their-face reminder that rapid growth and a promising pipeline are rare and come only for a high price in the health care industry.

Amgen originally offered to purchase Onyx for $120 per share almost seven weeks ago, but quickly found that offered rebuffed by Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), who was intent on shopping itself around and holding out for a better price. With Amgen now upping its offer to $9.5 billion, or $130 per share, some of the more serious bidders are beginning to bow out of the fray.

One of the potential bidders that have decided to step aside is oncology and hematology powerhouse Novartis AG (ADR) (NYSE:NVS). According to a Bloomberg report, Novartis AG (ADR) (NYSE:NVS) chairman Joerg Reinhardt is capping any future acquisition target at $10 billion, but he has no interest in acquiring Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) at such a steep price. That doesn’t, however, mean Novartis AG (ADR) (NYSE:NVS) isn’t on the prowl.

Source: Andrew Hecht, Flickr.

Novartis on the prowl
Novartis AG (ADR) (NYSE:NVS) is certainly no stranger to the dangers of the patent cliff. Like many of the world’s largest pharmaceutical companies, it’s seen some of its biggest money-making drugs fall victim to generic competition. Last year saw the loss of high blood pressure medication Diovan, which had contributed $5.7 billion (about 10% of annual sales) in revenue in 2011, and breast cancer medication Femara. Looking ahead to next year, its blockbuster leukemia treatment Gleevec will lose its patent exclusivity.

New drugs are helping to curtail this steep revenue drop-off, including relapse-remitting multiple sclerosis drug Gilenya, which saw sales rise 66% in the second quarter over the year-ago period, and kidney cancer drug Afinitor, which delivered a 77% spike in sales. But, there’s still nothing that can turn around an ailing pipeline quicker than an earnings-accretive acquisition.

Two companies on the radar
Here are two companies that I feel would be a good fit for Novartis AG (ADR) (NYSE:NVS).

Incyte Corporation (NASDAQ:INCY) – current market cap, $4.18 billion.
Incyte Corporation (NASDAQ:INCY) would make a lot of sense as a potential buy candidate for Novartis AG (ADR) (NYSE:NVS) given that the two companies already have an ongoing licensing pact with FDA-approved myelofibrosis drug Jakafi. Under the current deal, Incyte Corporation (NASDAQ:INCY) has the rights to Jakafi within the U.S. with Novartis claiming worldwide rights to the drug everywhere else. Jakafi (known as ruxolitinib in testing) is also being studied as a treatment for polycythemia vera, pancreatic cancer, and solid/hematologic tumors.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Biggest Airports in the World

The 5 Most Gang Infested Cities In America

The 34 Smartest Countries in the World

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!